MCL1 and melanoma: This MCL-1 dependence was driven by a significant downregulation of the sensitizer NOXA, which frees MCL-1 after treatment with ALK-TKIs to block therapy-induced apoptosis, as previously demonstrated in other solid tumors such as melanoma and rhabdomyosarcoma [25, 27].